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6KRUWUXQQLQJWLWOH³Sarilumab for previously-treated moderate or severe RA$Q(5*SHUVSHFWLYH´ 
Abstract 
As part of its single technology appraisal (STA) process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer (Sanofi Genzyme) of sarilumab (SAR; Kevzara®) to 
submit evidence of its clinical and cost-effectiveness for previously-treated moderate or severe 
rheumatoid arthritis (RA). The School of Health and Related Research Technology Appraisal Group at 
the University of Sheffield was commissioned to act as the independent Evidence Review Group 
(ERG). The ERG produced a detailed review of the evidence for the clinical and cost-effectiveness of 
WKHWHFKQRORJ\EDVHGXSRQWKHFRPSDQ\¶VVXEPLVVLRQWR1,&(7KHFOLQLFDOHIIHFWLYHQHVVHYLGHQFHLQ
WKH FRPSDQ\¶V VXEPLVVLRQ for SAR was based predominantly on five randomised controlled trials 
(RCTs) comparing the efficacy of SAR against adalimumab, tocilizumab or placebo. The clinical-
effectiveness review identified no head to head evidence on the efficacy of SAR against all the 
comparators within the scope. Therefore, the company performed three network meta-analyses (NMAs) 
in two different populations: two in patients who had had an inadequate response to conventional 
disease-modifying antirheumatic drugs (cDMARDs) (one for combination therapies and one for 
monotherapies), and the other one in patients who had had an inadequate response to tumour necrosis 
factor inhibitors (TNFi). 7KHFRPSDQ\¶V10$s concluded that SAR in combination with cDMARDs 
or as monotherapy has a statistically superior efficacy to cDMARDs and a comparable efficacy to most 
biologic disease-modifying antirheumatic drugs (bDMARDs) in both populations. The company 
submitted a Markov model that assessed the cost effectiveness of SAR from the perspective of the 
National Health Service (NHS) and Personal Social Services in seven different populations: (1) patients 
with severe RA who have had an inadequate response to cDMARDs (cDMARD-IR); (2) cDMARD-IR 
patients with severe RA for whom methotrexate (MTX) is contraindicated or not tolerated; (3) patients 
with severe RA who have had an inadequate response to a TNFi (TNFi-IR); (4) TNFi-IR patients with 
severe RA for whom rituximab (RTX) is not an option; (5) TNFi-IR patients with severe RA for whom 
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MTX is contraindicated or not tolerated; (6) TNFi-IR patients after RTX; and, (7) cDMARD-IR patients 
with moderate RA whose 28-joint Disease Activity Score (DAS28) is between 4.0 and 5.1. The 
FRPSDQ\¶V HFRQRPLF HYDOXDWLRQ UHVXOWV LQ incremental cost-effectiveness ratios (ICERs) lower than 
£20,000 per quality-adjusted life year (QALY) for SAR in combination with MTX or as monotherapy 
when the comparators were less effective and in ICERs higher than £60,000 per QALY for the 
comparators versus SAR when SAR was less effective, except: in TNFi-IR patients who are RTX 
eligible, the ICER for SAR + MTX compared with RTX + MTX is £130,691 per QALY; and in patients 
with moderate RA and a DAS28 > 4.0 the ICER of SAR + MTX compared with MTX is £38,254 per 
QALY gained. Following a critique of the model, the ERG undertook exploratory analyses after 
DSSO\LQJ WZR FKDQJHV WR WKH FRPSDQ\¶V PRGHO (1) using a latent class approach to model Health 
Assessment Questionnaire Disability Index (HAQ-DI) progression for patients on cDMARDs; and, (2) 
amending WKHFRPSDQ\¶VPRGHOOLQJRISDWLHQWSURJUHVVLRQIURPPRGHUDWHWRVHYHUH5$The ICERs 
HVWLPDWHGE\WKH(5*¶VH[SORUDWRU\DQDO\VHVIRU6$507;LQFUHDVHGWR£171,466 per QALY when 
compared with RTX + MTX in TNFi-IR patients who are RTX eligible and to £63,438 per QALY when 
compared with MTX in patients with moderate RA and a DAS28 > 4.0. The Appraisal Committee 
concluded that SAR in combination with MTX or as monotherapy is a cost-effective use of NHS 
resources in the considered populations except in TNFi-IR patients who are RTX eligible and in patients 
with moderate RA and DAS28 > 4.0.  
 
Word count: 597 
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Key points for decision makers 
x Sarilumab (SAR) has shown similar clinical efficacy to other recommended biologic disease-
modifying antirheumatic drugs (bDMARDs) or Janus kinase (JAK) inhibitors in previously-
treated moderate or severe rheumatoid arthritis (RA).  
x A confidential patient access scheme (PAS) has been agreed with the Department of Health 
under which SAR will be available to the National Health Service (NHS) at a reduced cost. 
x Estimated incremental cost-effectiveness ratios (ICERs) for SAR, in combination with MTX 
or as monotherapy, versus its comparators are within the range usually considered as a cost-
effective use of NHS resources in patients with severe RA where other bDMARDs have been 
recommended, except in patients who have had an inadequate response to a tumour necrosis 
factor inhibitor and who are eligible for rituximab (RTX). RTX is of similar clinical efficacy to 
SAR but has a significantly lower cost and therefore, RTX in combination with MTX should 
be preferred to SAR with MTX. 
x In patients with moderate RA and a 28-joint Disease Activity Score (DAS28) between 4.0 and 
5.1, the estimated ICER for SAR in combination with MTX versus MTX ranges from £38,254 
to £63,438 per quality-adjusted life year (QALY). 
 
1. Introduction 
The National Institute for Health and Care Excellence (NICE) is an independent organisation 
responsible for providing national guidance on promoting good health and preventing and treating ill 
health in priority areas with significant impact. Health technologies must be shown to be clinically 
effective and to represent a cost-effective use of National Health Service (NHS) resources in order for 
NICE to recommend their use within the NHS in England. The NICE Single Technology Appraisal 
(STA) process usually covers new single health technologies within a single indication, soon after their 
UK market authorisation.[1] Within the STA process, the company provides NICE with a written 
VXEPLVVLRQDORQJVLGHDPDWKHPDWLFDOPRGHOWKDWVXPPDULVHVWKHFRPSDQ\¶VHVWLPDWHVRIWKHFOLQLFDO
and cost effectiveness of the technology. This submission is reviewed by an external organisation 
independent of NICE (the Evidence Review Group [ERG]), which consults with clinical specialists and 
SURGXFHVD UHSRUW$IWHUFRQVLGHUDWLRQRI WKHFRPSDQ\¶V VXEPLVVLRQ WKH(5*UHSRUWDQG WHVWLPRQ\
from experts and other stakeholders, the NICE Appraisal Committee (AC) formulates preliminary 
guidance, the Appraisal Consultation Document (ACD), which indicates the initial decision of the AC 
regarding the recommendation (or not) of the technology. Stakeholders are then invited to comment on 
the submitted evidence and the ACD, after which a further ACD may be produced or a Final Appraisal 
Determination (FAD) issued, which is open to appeal. An ACD is not produced when the technology 
is recommended within its full marketing authorisation; in this case, a FAD is produced directly. 
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This paper presents a summary of the ERG report[2] for the STA of sarilumab (SAR), an anti-
interleukin-6 (IL-6) agent, for previously-treated moderate or severe rheumatoid arthritis (RA) and a 
summary of the subsequent development of the NICE guidance for the use of this technology in 
England. Full details of all relevant appraisal documents (including the appraisal scope, ERG report, 
company and consultee submissions, FAD and comments from consultees) can be found on the NICE 
website.[3]  
 
2. The Decision Problem 
RA is an autoimmune disease that causes chronic inflammation, progressive, irreversible joint damage, 
impaired joint function, pain and tenderness caused by swelling of the synovial lining of joints. The 
condition is associated with increasing disability and reduced health related quality of life.[4] The 
primary symptoms are pain, morning stiffness, swelling, tenderness, loss of movement, fatigue, and 
redness of the peripheral joints.[5, 6] RA is associated with substantial costs both directly (due to 
treatment acquisition and hospitalisation) and indirectly (due to reduced productivity).[7] The condition 
has long been reported as being associated with increased mortality,[8, 9] particularly due to 
cardiovascular events.[10] NICE estimates that there are 400,000 people in the United Kingdom (UK) 
with RA,[11] with approximately 26,000 incident cases per year.[12] RA is more prevalent in females 
(3.6 per 100,000 per year) than in males (1.5 per 100,000 per year).[13]  For both genders, the peak age 
of incidence in the UK is in the eighth decade of life, but all ages can develop the disease.[13]  
The measurement of improvement in RA symptoms has been assessed using two main classifications: 
American College of Rheumatology (ACR) responses[14] and European League Against Rheumatism 
(EULAR) responses.[15] In the UK, progression of RA is often monitored using the 28-joint disease 
activity score of 28 joints (DAS28). The EULAR response criteria use both the change in DAS28 and 
the absolute DAS28 score to classify a response as good, moderate or none.[15] Whilst EULAR 
response has been reported less frequently in RCTs than ACR responses,[16] it is much more closely 
aligned to the treatment continuation rules stipulated by NICE, which require at least a moderate 
EULAR response or a DAS28 improvement of more than 1.2 points to continue treatment with biologic 
disease-modifying antirheumatic drugs (bDMARDs).  
 
2.1 Current Treatment 
NICE recommends a combination of conventional disease-modifying antirheumatic drugs (cDMARDs) 
as first-line treatment for people with newly diagnosed RA, including methotrexate (MTX) and at least 
one other cDMARD plus short-term glucocorticoids, ideally beginning within 3 months of the onset of 
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persistent symptoms.[17] For patients who have severe active RA (defined as a DAS28 score greater 
than 5.1), NICE guidance recommends the use of the following bDMARDs and janus kinase (JAK) 
inhibitors: abatacept (ABT); adalimumab (ADA); certolizumab pegol (CZP); etanercept (ETN); 
golimumab (GOL); infliximab (IFX); tocilizumab (TCZ); baricitinib (BAR); and tofacitinib (TOF), 
each in combination with MTX after the failure to respond to cDMARD treatment.[18-21] For people 
with severe RA for whom MTX is contraindicated or has been withdrawn, NICE recommends the use 
of ADA, CZP, ETN, TCZ, TOF and BAR as monotherapy.[18-21] After the failure of the first TNFi, 
NICE recommends rituximab (RTX) in combination with MTX for the treatment of severe active 
RA.[22] If RTX is contraindicated or withdrawn because of an adverse event (AE), NICE recommends 
one of ABT, ADA, ETN, GOL, IFX, TCZ, CZP, TOF and BAR in combination with MTX [19-25]; if 
MTX is contraindicated or withdrawn because of an AE, NICE recommends ADA, ETN, CZP, TOF or 
BAR [19, 20, 22] as monotherapy. NICE also recommends TCZ in combination with MTX as a third 
line bDMARD after inadequate response to RTX in combination with MTX.[23] The treatment pathway 
is summarised in Figure 1. 
Figure 1: Treatment pathway recommended by NICE 
 
*followed by a treatment with a cDMARD (MTX unless not tolerated, SSZ otherwise) and BSC. 
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cDMARD: conventional disease-modifying antirheumatic drug; DAS28: 28-joint Disease Activity Score; BSC: best 
supportive care; MTX: methotrexate; ABT: abatacept; ADA: adalimumab; CZP: certolizumab pegol; ETN: etanercept; GOL: 
golimumab; IFX: infliximab; TCZ: tocilizumab; BAR: baricitinib; TOF: tofacitinib; RTX: rituximab; SSZ: sulfasalazine. 
NICE guidance recommends discontinuing treatment with bDMARDs or JAK inhibitors unless a 
moderate EULAR response is achieved at six months or if the response is not maintained [19, 20, 22-
25]. After treatment discontinuation, the next treatment in the sequence initiated.  
3. The Independent ERG Review 
In accordance with the process for STAs, the ERG and NICE had the opportunity to seek clarification 
RQVSHFLILFSRLQWVLQWKHFRPSDQ\¶Vsubmission (CS),[26] in response to which the company provided 
additional information.[27] 7KH(5*DOVRPRGLILHGWKHFRPSDQ\¶VGHFLVLRQDQDO\WLFPRGHOWRSURGXFH
an ERG base case and to assess the impact of alternative parameter values and assumptions on the 
PRGHO UHVXOWV7KH HYLGHQFH SUHVHQWHG LQ WKH FRPSDQ\¶V VXEPLVVLRQ DQG WKH (5*¶V UHYLHZ RI WKDW
evidence is summarised here. 
 
3.1 Clinical Evidence Provided by the Company 
Evidence was presented in the CS[26] for the efficacy of SAR in combination with MTX or as 
monotherapy in previously-treated moderate to severe RA. The key clinical effectiveness and safety 
evidence was based on five randomised controlled trials (RCTs). There were three RCTs in 
methotrexate (MTX) intolerant or inadequate response (MTX-IR) patients with RA (MOBILITY-
A,[28] MOBILITY-B,[29] and MONARCH[30]). Two RCTs (TARGET[31] and ASCERTAIN[32]) 
were in patients with RA who had had an inadequate response to bDMARDs (bDMARD-IR). One RCT 
(ASCERTAIN) compared SAR with tocilizumab (TCZ), another study (MONARCH) compared it 
against adalimumab (ADA), and the rest (MOBILITY-A, MOBILITY-B and TARGET) compared 
SAR against placebo (PBO). Additionally, one long-term extension study (EXTEND) was included. 
Three RCTs had 20% improvement in the American College of Rheumatology (ACR) score (ACR20) 
as their primary endpoint (MOBILITY-A, MOBILITY-B and TARGET). In the MTX-IR population, 
the RCTs showed a significant advantage (pLQ$&5UHVSRQVHVIRUOLFHQVHGGRVHVRISAR with 
concomitant MTX (SAR+MTX) over PBO + MTX (MOBILITY-A, MOBILITY-B), and a significant 
advantage (p<0.01) for SAR monotherapy over ADA monotherapy (MONARCH). In the bDMARD-
IR population, TARGET reported a significant advantage for SAR with a concomitant cDMARD over 
PBO+cDMARD on ACR20 (p<0.0001), ACR50 (pand ACR70 (p 
Network meta-analyses (NMA) were performed to assess the relative efficacy and safety of SAR versus 
the relevant comparators in patients with moderate-to-severe RA who were inadequate responders to 
cDMARDs (cDMARD-IR) or to tumour necrosis factor inhibitors (TNFi-IR). The efficacy outcome 
measures included in the NMA, which were assessed at 24 weeks (unless otherwise stated), were ACR 
responses, EULAR responses, the Health Assessment Questionnaire Disability Index (HAQ-DI), 
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DAS28 remission and modified Total Sharp Score (mTSS)). The outcome measures included in the 
safety NMA were serious infections and serious adverse events (SAEs). In the cDMARD-IR 
population, separate networks were used for the combination therapies and monotherapies.  
Results of the NMA showed that SAR in combination with cDMARDs or as monotherapy had similar 
or superior efficacy to its comparators. In the NMA for the cDMARD-IR population, SAR 200mg in 
combination with cDMARDs demonstrated statistical superiority to ABT combination, IFX 
combination and intravenous (IV) TCZ 4mg/kg on good EULAR response, and was comparable to 
GOL, TCZ IV 8mg/kg, rituximab (RTX) and SAR 150mg all in combination with cDMARDs. SAR 
200mg combination therapy was statistically inferior to CZP combination therapy on at least moderate 
EULAR response, but comparable to GOL, IFX, TCZ IV 4mg/kg and 8mg/kg, RTX and SAR 150mg 
all in combination with cDMARDs. In the NMA evaluating monotherapies in the cDMARD-IR 
population, SAR 200mg monotherapy showed statistically superiority to cDMARDs and ADA on 
EULAR responses, and was comparable to TCZ 8mg/kg. In the NMA for the TNFi-IR population, SAR 
200mg combination therapy showed statistically superiority to cDMARDs for all EULAR responses. 
For good EULAR response, SAR 200mg combination therapy was statistically superior to RTX 
combination therapy, and comparable to ABT and SAR 150mg combination therapies. For at least a 
moderate EULAR response, SAR 200mg combination therapy was statistically inferior to TCZ 8mg/kg 
and RTX combination therapies, and comparable to ABT, GOL and SAR 150mg combination therapies. 
Results for ACR responses were similar to those of EULAR responses. Regarding safety, SAR 200mg 
combination therapy was associated with significantly higher odds of SAEs at 52 weeks when compared 
to cDMARDs in the cDMARD-IR population. All other outcomes were not statistically significant.  
3.1.1 Critique of the Clinical Evidence and Interpretation 
The eligibility criteria applied in the selection of evidence for the clinical effectiveness review were 
considered by the ERG to be reasonable and generally consistent with the decision problem as outlined 
in the final NICE scope. The quality of the included RCTs was assessed using well-established and 
recognised criteria. The five SAR RCTs included were considered to be of good methodological quality 
in terms of randomisation, blinding and performing intention-to-treat analyses. 
 The results presented in the NMAs of clinical effectiveness should be treated with caution, as the 
statistically significant results of SAR 200mg compared with other bDMARD treatments (both as 
combination therapy and monotherapy) may be a consequence of underestimating the uncertainty in 
treatment effects resulting from the use of a fixed effect model. The ordered categorical ACR response 
and EULAR response data were dichotomised in the NMA, which ignores the natural ordering and 
correlations between the categories within the outcome measure. When a risk difference model was 
used for binary data, the probability of response was not constrained to be below or equal to 1, 
potentially producing invalid probability values. Furthermore, the TARGET and MOBILITY B trial 
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designs allowed SDWLHQWVZKRGLGQRWDFKLHYHDLPSURYHPHQWIURPEDVHOLQH at two consecutive 
assessments in the swollen joint count or tender joint count to switch to open-label SAR 200mg at 12 
and 16 weeks, respectively. Non-responder imputation was carried out for the control arm, assuming 
none of the non-responders in the cDMARD control group would become responders at 24 weeks, 
which may overestimate the relative treatment effect of SAR combination therapy versus cDMARDs.  
3.2 Cost-Effectiveness Evidence Provided by the Company 
The company supplied a de novo individual patient-level Markov model constructed in Microsoft 
Excel®. The model, which has a cycle length of 6 months, VLPXODWHVSDWLHQWV¶GLVHDVHSURJUHVVLRQs 
through the sequences of treatments being compared. For each treatment excluding best supportive care 
(BSC), patients may achieve good, moderate or no EULAR response, which is assessed at 6 months. 
The EULAR response rates for each treatment are based on the ACR response rates calculated using 
the FRPSDQ\¶VNMA. Patients who achieve moderate or good EULAR response are assumed to have 
an improvement in HAQ-DI and remain on treatment until loss of efficacy (as assessed by a clinician), 
or until they experience an AE or death. Patients who fail to achieve a moderate or good EULAR 
response discontinue treatment at 6 months and initiate the next treatment in the sequence. HAQ-DI 
whilst on treatment is assumed to remain constant on bDMARDs and SAR; conversely, whilst on 
cDMARDs and BSC, HAQ-DI is assumed to increasing at a constant annual rate of 0.045 and 0.06 
respectively. Time to treatment discontinuation for responders is dependent on the type of treatment 
(TNFi, IL-6, others) and is modelled using survival curves fitted to treatment discontinuation data from 
the Canadian observational database RHUMADATA. Upon treatment discontinuation, patients are 
assumed to experience a rebound in HAQ-DI equal to that achieved on treatment initiation and then 
start on the next treatment in the sequence. The mortality rate is assumed to be affected by the HAQ-
DI score of a patient at baseline. The model estimates the costs and quality-adjusted life years (QALYs) 
accrued RYHUSDWLHQWV¶UHPDLQLQJOLIHWLPHV(XUR4RO'LPHQVLRQV(4-5D) values are estimated based 
on a mapping algorithm from HAQ-DI and patient characteristics. Serious infection were the only AE 
included in the analyses. Hospitalisation costs and resource use estimates were based on HAQ-DI bands 
as in previous NICE technology appraisals.[18] Unit costs were taken from the British National 
Formulary and NHS Reference Costs. A confidential patient access scheme (PAS) has been agreed with 
the Department of Health under which SAR will be available to the NHS at a reduced cost. 
The FRPSDQ\¶V analyses relate to seven different populations of rheumatoid arthritis patients: (1) 
cDMARD-IR patients with severe RA who can tolerate MTX; (2) cDMARD-IR patients with severe 
RA for whom MTX is contraindicated or not tolerated; (3) TNFi-IR patients with severe RA and who 
are rituximab (RTX) eligible; (4) TNFi-IR patients with severe RA for whom RTX is not an option; (5) 
TNFi-IR patients with severe RA for whom MTX is contraindicated or not tolerated; (6) TNFi-IR 
patients with severe RA after treatment with RTX+MTX; and, (7) a subgroup of cDMARD-IR patients 
with moderate RA whose DAS28 scores are between 4.0 and 5.1. The definition of severe RA was a 
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DAS28 score higher than ZKLOVWPRGHUDWH5$ZDVGHILQHGDVD'$6!DQG%DVHOLQH
characteristics of patients are based on the relevant clinical SAR trials. The comparators included in the 
analyses are ABT (SC), TCZ (IV), TCZ (SC) and a blended comparator comprising a weighted average 
of all the TNFi-VWHUPHGµ71)LEXQGOH¶IRUSDWLHQWVZLWKVHYHUH5$DQG07;IRUSDWLHQWVZLWKPRGHUDWH
RA. The intervention as well as the comparators include further lines of treatment to replicate the 
treatment sequences recommended by NICE. 
The company presented their original analyses in the CS[26] and, XSRQ WKH (5*¶V UHTXHVW WKH\ 
presented revised analyses in the clarification responses[27] after addressing several issues identified 
by the ERG as detailed in Section 3.2.1. The revised analyses are presented here, as we believe that they 
DUH FORVHU WR WKH FRPSDQ\¶V LQWHQGHG EDVH FDVH WKDQ WKRVH UHSRUWHG LQ WKH &6 $FFRUGLQJ WR WKH
FRPSDQ\¶V UHYLVHGanalysis, in the cDMARD-IR patients with severe RA who could tolerate MTX, 
SAR+MTX dominated both indications of TCZ with concomitant MTX and the incremental cost-
effectiveness ratios (ICERs) for the TNFi bundle+MTX and ABT (SC)+MTX compared with 
SAR+MTX  were £69,884 and £117,482 per QALY gained respectively. In cDMARD-IR patients with 
severe RA who could not tolerate MTX, the ICER for SAR monotherapy versus the TNFi bundle was 
estimated to be £17,123 per QALY gained, whilst the ICER for both TCZ indications compared with 
SAR was in excess of £1,000,000 per QALY gained. In TNFi-IR patients for whom RTX+MTX was 
an option, the ICER for SAR+MTX compared with RTX+MTX was estimated to be £130,691 per 
QALY gained. In TNFi-IR patients for whom RTX is not an option, the ICER for all the comparators 
versus SAR+MTX was greater than £60,000 per QALY. For TNFi-IR patients who cannot tolerate 
MTX, the ICER for SAR monotherapy compared with a TNFi bundle was estimated to be £17,794 per 
QALY gained. In patients who have already received RTX+MTX, the ICER for both indications of 
TCZ compared with SAR+MTX were estimated to be greater than £130,000 per QALY gained. Finally, 
in cDMARD-IR patients with moderate RA and a DAS28 score higher than 4.0, the ICER for 
SAR+MTX was estimated to be £38,254 per QALY gained. The confidential PASs in place for TCZ 
and ABT were not included in these analyses. 
3.2.1 Critique of the Cost-Effectiveness Evidence and Interpretation 
7KHFRPSDQ\¶VPRGHOZDVEDVHGRQWKHPRGHOGHYHORSHGE\ WKHAssessment Group (AG) in NICE 
Technology Appraisal 375 (TA375) [18] but was an individual patient level Markov model rather than 
a discrete event simulation (DES). $IWHU DQ LQLWLDO HYDOXDWLRQ RI WKH FRPSDQ\¶V DQDO\VHV WKH (5* 
requested that the company perform new analyses after addressing a number of limitations. The 
company presented new analysis after addressing the following issues: (i) inadequate treatment 
sequences that did not reflect NICE recommendations or current practice: sequences did not include 
one cDMARD treatment after bDMARDs and included bDMARD treatments outside of the points in 
the pathway where they are recommended by NICE; (ii) patients with moderate RA were assumed to 
remain moderate and never progress to the severe state. The ERG requested the company to estimate 
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when the  patients would progress to severe RA by establishing a relationship between changes in HAQ-
DI and DAS28; (iii) using Malottki et al.[33] instead of the more accurate Hernandez et al.[34] for the 
mapping of HAQ-DI to EQ-5D; (iv) the limitations iQWKHFRPSDQ\¶V10$H[SODLQHGLQ6HFWLRQ 3.1.1; 
(v) using percentages of improvement of HAQ-DI instead of absolute changes; (vi) omission of 
rounding to the nearest valid HAQ-DI value; (vii) using a clinically implausible extrapolation curve for 
time to treatment discontinuation; (viii) using independent samples for the probabilities of ACR 
responses in the PSA instead of correlated samples from the CODA of the NMA; (ix) assuming 9 free 
doses of CZP instead of 10; and, (x) the inclusion of the speculative PAS discount of 15% applied to 
TCZ and ABT.  
Two main issues remain in the company¶V revised analyses are two. First, the assumption that the HAQ-
DI of patients on cDMARDs and BSC follow a linear trajectory is at odds with recent evidence[35, 36] 
that shows that the HAQ-DI progression in these patients is not linear. Additionally, the appraisal 
committee (AC) for TA375 accepted the non-linear trajectory of HAQ-DI using the latent class 
approach used by the AG.[16] 7KH (5* QRWHV WKDW WKH FRPSDQ\¶V DVVXPSWLRQ RI OLQHDU +$4-DI 
increase is likely to lead to underestimating the ICER for SAR+MTX versus MTX in the moderate RA 
population with a DAS28 score between 4.0 and 5.1. The second remaining LVVXHLQWKHFRPSDQ\¶V
amended model is the inadequate implementation of the transition from moderate to severe RA. In the 
FRPSDQ\¶VDPHQGHGPRGHOSDWLHQWVJRWKURXJKWKHWUHDWPHQWVHTXHQFHIRUPRGHUDWHSDWLHQWVDQGRQO\
once they reach BSC they might transition to the severe RA, if their estimated DAS28 is above 5.1.  
However, patients should progress to the severe sequences the moment their estimated DAS28 score 
increases above 5.1, without waiting until they have reached the end of the moderate sequence.  
3.3 Additional Work Undertaken by the ERG 
The ERG undertook exploratory analyses after implementing two FKDQJHVLQWKHFRPSDQ\¶VDPHQGHG
model to address the perceived two remaining limitations. First, implementing the latent class approach 
of non-linear HAQ-DI trajectories used in TA375[16] and applying it to patients on cDMARDs or BSC. 
And second, amending the transition of moderate RA patients to the severe state by: (1) calculating the 
SDWLHQW¶V'$6DWHDFKF\FOHE\applying the estimated change in DAS28 based on change in HAQ-
DI from baselinH XVLQJ WKH FRPSDQ\¶V OLQHDU UHJUHVVLRQ WR WKH SDWLHQW¶V EDVHOLQH '$6 DQG 
moving patients to the treatment sequences recommended for severe RA once their estimated DAS28 
increased above 5.1. 
$FFRUGLQJ WR WKH (5*¶V H[SORUDWRU\ DQDO\VHV LQ F'0$5'-IR patients with severe RA who can 
tolerate MTX, SAR + MTX was estimated to dominate both indications of TCZ with concomitant MTX 
and the ICERs for TNFi bundle + MTX and ABT (SC) + MTX compared with SAR + MTX are 
estimated to be in excess of £150,000 per QALY gained. In cDMARD-IR patients with severe RA for 
whom MTX was contraindicated or not tolerated, the ICER for SAR monotherapy compared with TNFi 
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bundle monotherapy was estimated to be £34,422 per QALY gained, whilst the ICERs for both 
indications of TCZ compared with SAR monotherapy where estimated to be in excess of £1,500,000 
per QALY gained. In TNFi-IR patients with severe RA who can tolerate RTX and MTX the ICER for 
SAR+MTX compared with RTX+MTX was estimated to be £171,466 per QALY gained. In TNFi-IR 
patients with severe RA for whom RTX is not an option, SAR + MTX was estimated to result in an 
ICER of £34,979 per QALY gained compared with TNFi bundle whilst the ICER for both TCZ 
indications with concomitant MTX compared with SAR + MTX was estimated to be in excess of 
£195,000. In TNFi-IR patients with severe RA for whom MTX is contraindicated or not tolerated, the 
ICER for SAR monotherapy compared with TNFi bundle was estimated to be £31,433 per QALY 
gained. In TNFi-IR patients who have already received RTX+MTX, the ICERs for both indications of 
TCZ with concomitant MTX compared with SAR+MTX were estimated to be in excess of £200,000 
per QALY gained. In cDMARD-IR patients moderate RA and a DAS28 higher than 4.0, a sequence 
starting with SAR+MTX compared with MTX was estimated to result in an ICER of £63,438 per QALY 
gained. Table 1 shows a summary of the results presented by the company and the ERG. 
Table 1: ICERs versus SAR + MTX or SAR monotherapy (depending on population) 
[Insert Table 1 here] 
The confidential PASs in place for ABT and TCZ were not included in these analyses but the ERG 
provided NICE with analyses including the confidential PASs in a confidential appendix. 
3.4 Conclusions of the ERG Report 
The key clinical effectiveness evidence for SAR was based on five RCTs and one long-term extension 
study in two different populations: MTX-IR and bDMARD-IR. In the MTX-IR population, the RCTs 
showed a significant advantage in ACR20 responses for licensed doses of SAR+MTX over PBO+MTX, 
and a significant advantage for SAR monotherapy over ADA monotherapy. In the TNFi-IR population, 
there was a significant advantage for SAR+cDMARD over PBO+cDMARD in ACR20 responses and 
the trials reported significantly favourable results for licensed doses of SAR over comparators for 
improvement in HAQ-DI. According to the results of the NMAs undertaken by the company, in the 
SAR in combination with cDMARDs or as monotherapy demonstrated statistically superiority to 
cDMARDs in the relevant efficacy outcome measures and showed comparable or statistically superior 
efficacy to most of its bDMARD comparators. 
The company presented results of analyses based on a de novo economic model that was largely based 
on the model developed by the AG in TA375. In their clarification response the company presented a 
new set of analyses after addressing several issues identified by the ERG. The ERG undertook 
exploratory analyses after addressing two remaining issues: the HAQ-DI trajectories of patients on 
cDMARDs and BSC and the transition of patients from moderate to severe RA. In cDMARD-IR 
12 
 
patients with severe RA who could tolerate MTX, both the FRPSDQ\¶V DQG WKH (5*¶V analyses 
concluded that SAR + MTX dominates both indications of TCZ in combination with MTX and that the 
ICER of all other comparators versus SAR +MTX is in excess of £75,000 per QALY. In cDMARD-IR 
MTX-intolerant patients with severe RA, the ICER for SAR monotherapy versus TNFi bundle 
monotherapy is estimated to be £17,123 and £34,422 SHU4$/<EDVHGRQWKHFRPSDQ\¶VDQDO\VHVDQG
WKH(5*¶VDQDO\VHVUHVSHFWLYHO\ whilst the ICER of TCZ monotherapies (SC and IV) is estimated to be 
in excess of £1,500,000 per QALY. In TNFi-IR RTX-eligible patients, ERWK WKHFRPSDQ\¶VDQG WKH
(5*¶VDQDO\VLVFRLQFLGHWKDWWKH,&(5IRUSAR + MTX versus RTX + MTX is in excess of £130,000 
per QALY compared with. In TNFi-IR patients for whom RTX is not an option, the ERG and the 
company used different treatment sequences, which led to different results: DFFRUGLQJWRWKHFRPSDQ\¶V
analyses the ICERs of all comparators versus SAR + MTX are in excess of £64,602 per QALY gained 
whilst DFFRUGLQJWRWKH(5*¶VDQDO\VHV the ICER of SAR+MTX compared with TNFi bundle + MTX 
is £34,979 but SAR + MTX dominates ABT + MTX and the ICERs of both indications of TCZ in 
combination with MTX versus SAR + MTX are in excess of £195,000. In TNFi-IR MTX-intolerant 
patients, the ICER for SAR monotherapy versus TNFi bundle monotherapy is estimated to be £17,794 
and £31,433 per QALY according to the FRPSDQ\¶V DQG WKH (5*¶V DQDO\VHV respectively. The 
difference between the ICERs is due to the ERG applying a different HAQ-DI progression whilst on 
cDMARDs. In TNFi-IR patients who have had RTX + MTX, the ICERs for both indications of TCZ + 
MTX versus SAR + MTX are estimated to be in excess of £130,000 per QALY according to the 
FRPSDQ\¶VDQGWKH(5*¶VDQDO\VHV In cDMARD-IR patients with moderate RA, SAR + MTX versus 
MTX is estimated to result in ICERs of £38,254 and £63,438 per QALY gained according to the 
FRPSDQ\¶VDQGWKH (5*¶VDQDO\VHV respectively. The confidential PASs in place for TCZ and ABT 
have not been included in these analyses. 
4. Key Methodological Issues 
The company used fixed effect models used when data were sparse. However, too few studies should 
not rule out a random effects analysis. If heterogeneity is expected, then a random effect model should 
be applied with careful consideration of the prior for the between-study variance. The statistically 
significant results of SAR compared with other bDMARD treatments may be as a result of using a fixed 
effect model, which underestimates uncertainty in the treatment effects. A limitation remaining in the 
revised NMA is that the company dichotomised the ordered categorical ACR and EULAR response 
data, which ignores the natural ordering and correlations between the categories within the outcome 
measure. 
7KH FRPSDQ\¶V RULJLQDO HFRQRPLF DQDO\VLV FRQWDLQHG VHYHUDO LVVXHV WKH PRVW LPSRUWDQW EHLQJ 
inadequate sequences that did not reflect NICE recommendations; (2) patients with moderate RA were 
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assumed never to transition to severe RA; and, (3) assuming a constant HAQ-DI increase rate for 
patients on cDMARDs or BSC instead of using long-term HAQ-DI progression data.  
Finally, including the TNFi-s independently would have been more informative than using a blended 
comparator, given the differences in cost and efficacy of different TNFi-s and the fact that their market 
shares may be changing.  
5. National Institute for Health and Care Excellence Guidance  
In August 2017, on the basis of the evidence available (including verbal testimony of invited clinical 
experts and patient representatives), the NICE AC produced guidance that SAR in combination with 
MTX was recommended as an option for treating active RA in: (1) adults whose disease is severe 
(DAS28 > 5.1) and has responded inadequately to intensive therapy with a combination of cDMARDs; 
(2) adults whose disease is severe and has responded inadequately to at least one bDMARD if they 
cannot have rituximab; (3) adults whose disease has responded inadequately to RTX and at least 1 
bDMARD. The NICE AC also recommended SAR as monotherapy for people who cannot tolerate 
MTX who met the criteria in (1) and (2). All the recommendations where subject to the company 
providing SAR with the discount agreed in the PAS. 
5.1 Consideration of Clinical and Cost-Effectiveness Issues Included in the Final Appraisal 
Determination (FAD) 
This section summarises the key issues considered by the AC. The full list can be found in the FAD.[3]   
 
5.1.1 Current Clinical Management 
The AC considered the evidence submitted by Sanofi and the current clinical management of 
previously-treated moderate or severe RA in England. The AC noted that SAR can be used in five 
different points in the treatment pathway and that the NICE technology appraisal guidance already 
exists for these points in the pathway. The AC heard from clinical and patient experts that it would be 
helpful to have new treatments that can be used at various points in the treatment pathway. 
 
5.1.2 Uncertainties in the Clinical evidence 
The AC considered the clinical evidence presented by the company from five randomised controlled 
trials and concluded that the trials were relevant and adequate for its decision-making. The AC accepted 
that the results showed that SAR plus MTX is more clinically effective than placebo plus MTX and 
SAR monotherapy is more clinically effective than ADA monotherapy in cDMARD-IR patients. It also 
acknowledged that SAR is more clinically effective than cDMARDs in TNFi-IR patients but that SAR 
has an increased rate of AEs compared with MTX. The AC noted that because the only direct evidence 
available on the comparative effectiveness of SAR and bDMARDs was with ADA, the company did 
NMAs for different populations. 7KHFRPPLWWHHFRQVLGHUHGWKHFRPSDQ\¶VRULJLQDO10$VDVZHOODV
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the NMAs requested by the ERG and concluded that the methods used by the company were in line 
with previous NICE technology appraisals and that the NMAs were therefore suitable for decision-
making.  
 
5.1.3 Uncertainties in the Economic Modelling  
The AC considered the FRPSDQ\¶VPRGHOVWUXFWXUHWREHDSSURSULDWHIRUGHFLVLRQ-making, as well as 
the methods for calculating utilities and costs. However, the AC considered that the treatment sequences 
XVHGLQWKHDQDO\VHVZHUHDSSURSULDWHRQO\DIWHUWKH(5*¶VFRUUHFWLRQV7KH$&ZDVFRQFHUQHGwith 
the implementation of HAQ-DI progression in response to treatment but concluded that the non-linear 
approach used by the ERG was appropriate and that WKH(5*¶VDGGLWLRQDODQDO\VHV were suitable for 
decision making. Finally, the committee considered that the (5*¶VFKDQJHVWRKRZSDWLHQWVSURJUHVV
from treatment for moderate disease to treatment for severe disease were appropriate. 
6. Conclusions 
The evidence suggests that SAR in combination with MTX or as monotherapy has a similar efficacy 
for treating moderate to severe RA to that of other bDMARDs, especially TCZ, another IL-6 already 
recommended by NICE. The economic analyses conducted by the company and the ERG estimated 
ICERs within the range usually considered by NICE as a cost-effective use of NHS resources for SAR 
in combination with MTX or as monotherapy versus some or all of its comparators in the considered 
populations, excluding TNFi-IR RTX-eligible patients and patients with moderate RA. Consequently, 
NICE recommended SAR in combination with MTX as an option for patients with severe RA who can 
tolerate MTX if: they are cDMARD-IR; they are TNFi-IR and RTX is not an option; or, they are TNFi-
IR and have already been treated with RTX + MTX. NICE recommended SAR monotherapy for 
cDMARD-IR and TNFi-IR patients with severe RA who cannot tolerate MTX. 
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